|Videos|July 2, 2013

Episode 14 - Concerns about Rising Costs of Treatment

During this segment, the panelists discuss their concerns about the rising costs of drugs currently available to treat multiple sclerosis (MS).

Gary M. Owens, MD, states that it is unclear why drug prices continue to rise, especially when certain options have been available for years. Dr Owens further explains there is no single formula to determine a return on investment for newer agents.

Because the drugs to treat MS are extremely expensive and difficult for patients to afford, Dr Owens and Leslie Fish, PharmD, suggest that when reviewing and negotiating the price of a therapy option, there is a need for transparency and comparative effectiveness.



Related to this article

CAR T-cell therapy | Image: AdobeStock
In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."